In the last trading session, 1.66 million shares of the Janux Therapeutics Inc (NASDAQ:JANX) were traded, and its beta was 3.28. Most recently the company’s share price was $64.99, and it changed around -$1.31 or -1.98% from the last close, which brings the market valuation of the company to $3.68B. JANX currently trades at a discount to its 52-week high of $71.71, offering almost -10.34% off that amount. The share price’s 52-week low was $7.79, which indicates that the current value has risen by an impressive 88.01% since then. We note from Janux Therapeutics Inc’s average daily trading volume that its 10-day average is 2.39 million shares, with the 3-month average coming to 918.42K.

Janux Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended JANX as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Janux Therapeutics Inc is expected to report earnings per share of -0.42 for the current quarter.

Janux Therapeutics Inc (NASDAQ:JANX) trade information

Instantly JANX has showed a red trend with a performance of -1.98% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 71.71 on recent trading dayincreased the stock’s daily price by 9.37%. The company’s shares are currently up 505.69% year-to-date, but still up 43.75% over the last five days. On the other hand, Janux Therapeutics Inc (NASDAQ:JANX) is 18.40% up in the 30-day period. We can see from the shorts that 4.19 million shares have been sold at a short interest cover period of 6.05 day(s).

The consensus price target as assigned by Wall Street analysts is $69.5, which translates to bulls needing to increase their stock price by 6.49% from its current value. Analyst projections state that JANX is forecast to be at a low of $42 and a high of $100.

Janux Therapeutics Inc (JANX) estimates and forecasts

Janux Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 47.17 percent over the past six months and at a -2.27% annual growth rate that is well below the industry average of 17.10%. The year-over-year growth rate is expected to be 37.01%, up from the previous year.

Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 490k in revenue for the current quarter. 9 analysts expect Janux Therapeutics Inc to make 1.21M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.46M and 1.25M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -80.09%. Forecasts for the next quarter put sales growth at -3.29%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -92.62%.

JANX Dividends

Janux Therapeutics Inc’s next quarterly earnings report is expected to be released in January.

Janux Therapeutics Inc (NASDAQ:JANX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 6.98% of Janux Therapeutics Inc shares, and 86.38% of them are in the hands of institutional investors. The stock currently has a share float of 92.87%. Janux Therapeutics Inc stock is held by 237.0 institutions, with RA CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 18.6864% of the shares, which is about 9.17 million shares worth $383.95 million.

FMR LLC, with 15.8566% or 7.78 million shares worth $325.8 million as of 2024-06-30, holds the second largest percentage of outstanding shares.